As a kick-off activity for the BiomarkerBay consortium, a whole week of networking events are planned in the booming Massachusetts Life Sciences arena.
A BiomarkerBay delegation will be present and connect with start-ups and longstanding pharmaceutical companies, life science incubators, like the Cambridge Innovation Center and Lab Central, and with world-renowned research institutes, like the MIT McGovern Institute and the AgingWell Institute. In addition, one-to-one meetings are planned with several pharmaceutical and diagnostics companies to explore business opportunities. BiomarkerBay will be represented by Ymke van der Geld and Martin Smit, from the Management Board of BiomarkerBay, and Ep Oosting for ABL and Dawm Moore for QPS, from the BiomarkerBay partners.
In collaboration with Rudy Schreiber, from Suadeo-consulting, and Walter de Wit, Julia Knoeff and Cato Bechtold from the Holland Innovation Network, BiomarkerBay has organized the symposium “Increasing Success in Drug Discovery by Biomarkers: An Interactive Symposium” with special focus on the roles of biomarker research in drug discovery and the challenges in the confirmation of newly-discovered biomarkers. A section of the symposium will be dedicated to the recent development in biomarker discovery in Alzheimer’s disease. For more information, please visit our event page, here.
